A Phase 3 interventional study of Investigational mRNA-1273.815 and Licensed Spikevax Vaccine in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 7 sites in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..
Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 20th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2024, is one of 6 in phase 3, and was the 27th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 10 · Phase 4 4
First in 2020; this study’s year is marked. 3 started in 2024.
This study's enrollment of 217 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 988 across the 22 interventional studies, 8,691 across the 12 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
4 of the studies in COVID-19 by Moderna, Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
| NCT06189053ModernaTX, Inc.A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX) | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in COVID-19 by Moderna, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 217 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants of may be enrolled in the study if the participant fulfills all of the following criteria:
Exclusion Criteria:
Receipt of the following:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Investigational mRNA-1273.815 by intramuscular injection.
Biological: Investigational mRNA-1273.815
Participants will receive a licensed Spikevax vaccine by intramuscular injection.
Biological: Licensed Spikevax Vaccine
Sterile solution for injection
Commercially available formulation
Geometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15
Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values reported greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 38 arbitrary unit (AU)/milliliter (mL) and ULOQ was 6960 AU/mL. 95% confidence interval (CI) of GM value was calculated based on the t-distribution of the log-transformed values for antibodies, then back transformed to the original scale for presentation.
Time frame: Day 15
Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) of Special Interest (AESIs), and AEs Leading to Withdrawal From the Study
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. Number of participants with SAEs, AESIs, and AEs leading to discontinuation up to Day 15 are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Day 15
Seroresponse Rate of nAb Against the SARS-CoV-2-specific Strain: Percentage of Participants With Seroresponse
Seroresponse at a participant level was defined as a change from baseline below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if baseline was equal to or above the LLOQ. LLOQ was 38 AU/mL.
Time frame: Day 15
| Milestone | Investigational mRNA-1273.815 | Licensed Spikevax Vaccine |
|---|---|---|
| Started | 108 | 109 |
| Received study vaccination | 106 | 109 |
| Completed | 105 | 109 |
| Not completed | 3 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 |
Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values reported greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 38 arbitrary unit (AU)/milliliter (mL) and ULOQ was 6960 AU/mL. 95% confidence interval (CI) of GM value was calculated based on the t-distribution of the log-transformed values for antibodies, then back transformed to the original scale for presentation.
| AU/mL | Investigational mRNA-1273.815 | Licensed Spikevax Vaccine |
|---|---|---|
| Geometric Mean (GM) Value of Neutralizing Antibodies (nAbs) Against SARS-CoV-2-specific Strain at Day 15 | 1180.55 (927.67 to 1502.38) | 1300.25 (1056.39 to 1600.40) |
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. Number of participants with SAEs, AESIs, and AEs leading to discontinuation up to Day 15 are reported in this outcome measure. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Investigational mRNA-1273.815 | Licensed Spikevax Vaccine |
|---|---|---|
| SAEs | 1 | 0 |
| AESIs | 0 | 0 |
| AEs Leading to Withdrawal | 0 | 0 |
Seroresponse at a participant level was defined as a change from baseline below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if baseline was equal to or above the LLOQ. LLOQ was 38 AU/mL.
| percentage of participants | Investigational mRNA-1273.815 | Licensed Spikevax Vaccine |
|---|---|---|
| Seroresponse Rate of nAb Against the SARS-CoV-2-specific Strain: Percentage of Participants With Seroresponse | 66.0 (56.0 to 75.1) | 69.2 (59.4 to 77.9) |
Collected over Day 1 through Day 15. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Investigational mRNA-1273.815 | 0/108 (0%) | 1/106 (0.9%) | 0/106 (0%) |
| Licensed Spikevax Vaccine | 0/109 (0%) | 0/109 (0%) | 0/109 (0%) |
| Event | Investigational mRNA-1273.815 | Licensed Spikevax Vaccine |
|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 1/106 | 0/109 |
Safety Set included all enrolled participants who received study drug.
| Age, Continuous(years) | Investigational mRNA-1273.815 | Licensed Spikevax Vaccine | Total |
|---|---|---|---|
| Mean | 48.2 ± 16.09 | 46.0 ± 17.47 | 47.1 ± 16.80 |
| Sex: Female, Male(Participants) | Investigational mRNA-1273.815 | Licensed Spikevax Vaccine | Total |
|---|---|---|---|
| Female | 48 | 52 | 100 |
| Male | 58 | 57 | 115 |
| Ethnicity (NIH/OMB)(Participants) | Investigational mRNA-1273.815 | Licensed Spikevax Vaccine | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 8 |
| Not Hispanic or Latino | 93 | 85 | 178 |
| Unknown or Not Reported | 10 | 19 | 29 |
| Race/Ethnicity, Customized(Participants) | Investigational mRNA-1273.815 | Licensed Spikevax Vaccine | Total |
|---|---|---|---|
| Race — White | 82 | 92 | 174 |
| Race — Black or African American | 1 | 1 | 2 |
| Race — Asian | 12 | 10 | 22 |
| Race — Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| Race — Multiple | 2 | 3 | 5 |
| Race — Other | 7 | 2 | 9 |
| Race — Not reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2024 to primary completion in May 2024, 1 month.
Results were first posted in May 2025, 1 year after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 1 month is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.